NOVEL RP-HPLC METHOD DEVELOPMENT AND VALIDATION FOR ESTIMATION OF TELMISARTAN AND NEBIVOLOL HCL IN PHARMACEUTICAL DOSAGE FORM
DOI:
https://doi.org/10.22159/ajpcr.2018.v11i9.27016Keywords:
Reversed-phase high-performance liquid chromatography, Telmisartan, Nebivolol hydrochloride, Simultaneous estimationAbstract
Objective: A simple, accurate, precise, robust reverse phase high performance liquid chromatography (RP-HPLC) method was developed for the estimation of telmisartan and nebivolol hydrochloride (HCl) simultaneously in its combined dosage form.
Methods: The compounds were well resolved in an isocratic method using the mobile phase composition of acetonitrile: Buffer (potassium dihydrogen orthophosphate pH adjusted 3.1 with orthophosphoric acid) in a ratio of 40:60 v/v at a flow rate of 1.2 ml/min using C18 Shim-pack (150 mm × 4.6 mm, 5 μ) column. The detection was carried out at 280 nm.
Results: The retention time of telmisartan and nebivolol HCl was 4.8 min and 6.5 min, respectively. The developed method was validated by evaluating various validation parameters such as linearity, precision, accuracy, robustness, specificity, limit of detection, and limit of quantification according to the international council for harmonization guidelines. The standard calibration curve was obtained in the concentration range of 24–56 μg/ml for telmisartan and 3–7 μg/ml for nebivolol HCl. The overall average % recovery was found out to be 100.35 for telmisartan and 98.84 for nebivolol HCl.
Conclusion: Statistical analysis of the data showed that the method is reproducible and selective for the estimation of telmisartan and nebivolol HCl. The proposed method could be used for analysis of telmisartan and nebivolol HCl in their dosage form.
Downloads
References
Beckett AH, Stenlake JB. Practical Pharmaceutical Chemistry. 4th ed., Vol. 11. Daryaganj, New Delhi: Bloomsbury Publishing PLC; 1997. p. 278.
The Indian Pharmacopoeia Commission. Indian Pharmacopoeia. 6th ed., Vol. 3. Ghaziabad: The Indian Pharmacopoeia Commission; 2010. p. 2186.
Mahesh M, Kumanan R, Jayaveer KN. Isocratic RP-HPLC UV method development and validation for the simultaneous estimation of hydrochlorothiazide and ramipril in tablet dosage form and bulk drug. Int J Curr Pharm Res 2011;3:119-23.
Shah DA, Bhatt KK, Mehta RS, Baldania SL. Determination of nebivolol hydrochloride and hydrochlorothiazide in tablets by first-order derivative spectrophotometry and liquid chromatography. J AOAC 2008;5:1075-82.
Nekkala K, Shanmukha V, Kumar J, Ramchandran D, Ganji R, Ganta S. Method development and validation of stability indicating RP-HPLC method for simultaneous estimation nebivolol HCl and valsartan in bulk and its pharmaceutical formulation. Am J Adv Drug Deliv 2014;2:624 37.
ICH. Q2 (R1), Harmonized Tripartite Guideline, Validation of Analytical Procedures Text and Methodology. Geneva: International Conference on Harmonization (ICH); 2005.
Surekha LM, Kumara GS, Ashwini GL. Development and validation RP-HPLC method for the estimation of telmisartan in bulk and tablet dosage form. Int J Drug Dev Res 2012;4:200-5.
Shinde R, Bohir SI, Pawar NS, Yadav SB, Ghumatkar AS, Bhagwat AM. Simultaneous determination of valsartan and nebivolol HCl in tablet dosage form by RP-HPLC. Asian J Research in Chem 2009;4:519-22.
Patel ND, Mehta R, Captain AD, Karkhanis VV, Patel PD, Chavda AA. Development and validation of stability indicating RP-HPLC method for simultaneous estimation of nebivolol hydrochloride and cilnidipine in tablet dosage form. J Pharm Sci Bioscientific Res 2017;7:140-7.
Hafez H, Abdullah AE, Abdelaziz LM. Stability indicating HPLC method for simultaneous determination of several angiotensin- II-receptor antagonist in their dosage forms. Pharmaceutica Analytica Acta 2012;8:1-11.
Marineni B, Reddy TS. Development and validation of stability-indicating RP-HPLC assay method for azacytidine and its bulk drug. Int J Pharm Pharm Sci 2014;6:240-4.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.